FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989666329> ?p ?o ?g. }

• W2989666329 endingPage "318" @default.
• W2989666329 startingPage "318" @default.
• W2989666329 abstract "The discovery that thalidomide derivatives recruit the E3 ligase CRBN to induce neomorphic degradation of proteins critical for multiple myeloma (MM) cells stimulated the research into proteolysis-targeting chimeric compounds (PROTACs), led to development of several CRBN- or VHL-based PROTACs against various oncoproteins and put a new spotlight on the biology and therapeutic targeting of E3 ligases in human neoplasias. However, so far only a few of the ~600 known/presumed E3 ligases have been leveraged for generation of PROTACs. The mechanisms regulating the function of most E3 ligases have not been systematically examined. Because the function of an E3 ligase is considered essential for anti-tumor activity of its respective PROTACs, we applied CRISPR knock-out (KO) systems to identify candidate regulators of E3 ligase function, via characterizing the the network of genes which modulate MM cell responses to PROTACs. We thus performed genome-scale CRISPR-based gene editing (for loss-of-function, LOF) studies in MM.1S cells treated with PROTACs targeting BET bromodomain proteins through MDM2 (A1874), CRBN (dBET6) or VHL (ARV-771 or MZ-1) or targeting CDK9 through CRBN (Thal-SNS-032); and validated key hits with individual sgRNAs in different MM cell lines. The top individual LOF events conferring resistance to PROTACs did not involve a compensatory mechanism or work-around the loss of the respective oncoprotein, but were predominantly associated with LOF of the respective E3 ligase; or with LOF for genes with known or plausible role in regulating the respective E3 ligases. For instance, sgRNAs against members of the COP9 signalosome complex decreased MM cell responses to CRBN- and (to a lesser extent) VHL-, but not MDM2-based PROTACs. PROTACs leveraging different E3 ligases were regulated by different cullin ring ligase (CRL) complex members (e.g. CUL2, RBX1, TCEB1, TCEB2 for VHL- vs. DDB1 for CRBN- vs. no CRL member for MDM2-based PROTACs) or E2 conjugating enzymes (UBE2R2 vs. UBE2G1 for VHL- vs. CRBN-based PROTACs). Collectively, these results suggest that MDM2 regulation is largely CRL- and COP9-signalosome independent; while VHL regulation is less COP9 signalosome-dependent compared to CRBN. These mechanistic differences suggest that PROTACs targeting the same oncoprotein through different E3 ligases should not be associated with cross-resistance, a result which we validated in experiments involving sequential administration of different PROTACs against BRD4/3/2. In turn, this observation implied that developing PROTACs that leverage a more extended spectrum of E3 ligases may facilitate sequential uses of existing and these new PROTACs to delay or prevent treatment resistance. Building on results of our genome-scale CRISPR essentiality screens, we examined the dependency landscape of known E3 ligases of MM (n=20 cell lines) and 500+ non-MM cell lines. CRBN is redundant for nearly all MM or non-MM cell lines tested, while most other E3 ligases leveraged for PROTACs (e.g. MDM2, BIRC2, DCAF15, DCAF16, RNF114) are essential for only modest or small subsets of human cancer cell lines, suggesting that resistance to respective PROTACs may readily emerge through LOF of these E3 ligases without major fitness cost to tumor cells. We thus sought to identify E3 ligases which are highly expressed in subsets of human tumor cell lines (at levels well above the large majority of normal tissues) and are major dependencies for these high expressor cell lines: we identified MDM2 as a major dependency for p53-wild-type cell lines (consistent with MDM2 role as E3 ligase for p53) and we validated this result by documenting the preferential activity of a MDM2-based PROTAC for BRD4/3/2 against p53 wild-type cells. We also identified other E3 ligases genes with well-known roles in tumor cell biology (e.g. members of anaphase promoting complex/cyclosome); as well as E3 ligases (e.g. KCMF1, RNF4) which, to our knowledge, have not been leveraged for design of PROTACs, but warrant consideration given their patterns of essentiality in high expressor tumor cells. Our study provides insights on differential regulation and distinct patterns of essentiality for different E3 ligases and informs the design of new PROTACs which leverage different E3 ligases to help delay/overcome treatment resistance in MM and beyond. Disclosures Schlossman: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Richardson:Oncopeptides: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees. Ebert:Broad Institute: Other: Contributor to a patent filing on this technology that is held by the Broad Institute.; Celgene: Research Funding; Deerfield: Research Funding. Tsherniak:Tango Therapeutics: Consultancy. Boise:Genentech Inc.: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Research Funding. Gray:Gatekeeper, Syros, Petra, C4, B2S and Soltego.: Equity Ownership; Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield and Sanofi.: Equity Ownership, Research Funding. Mitsiades:Takeda: Other: employment of a relative ; Ionis Pharmaceuticals: Honoraria; Fate Therapeutics: Honoraria; Arch Oncology: Research Funding; Sanofi: Research Funding; Karyopharm: Research Funding; Abbvie: Research Funding; TEVA: Research Funding; EMD Serono: Research Funding; Janssen/Johnson & Johnson: Research Funding." @default.
• W2989666329 created "2019-12-05" @default.
• W2989666329 creator A5005661878 @default.
• W2989666329 creator A5006261099 @default.
• W2989666329 creator A5012712111 @default.
• W2989666329 creator A5017218287 @default.
• W2989666329 creator A5022352605 @default.
• W2989666329 creator A5023112790 @default.
• W2989666329 creator A5023676277 @default.
• W2989666329 creator A5023902781 @default.
• W2989666329 creator A5027278060 @default.
• W2989666329 creator A5027328800 @default.
• W2989666329 creator A5027607604 @default.
• W2989666329 creator A5033004996 @default.
• W2989666329 creator A5037115007 @default.
• W2989666329 creator A5039325835 @default.
• W2989666329 creator A5039865368 @default.
• W2989666329 creator A5040526903 @default.
• W2989666329 creator A5043526996 @default.
• W2989666329 creator A5046430988 @default.
• W2989666329 creator A5047985390 @default.
• W2989666329 creator A5049272086 @default.
• W2989666329 creator A5049711954 @default.
• W2989666329 creator A5049971068 @default.
• W2989666329 creator A5055000089 @default.
• W2989666329 creator A5060671712 @default.
• W2989666329 creator A5060982277 @default.
• W2989666329 creator A5063875415 @default.
• W2989666329 creator A5064538334 @default.
• W2989666329 creator A5068511166 @default.
• W2989666329 creator A5069655687 @default.
• W2989666329 creator A5070668676 @default.
• W2989666329 creator A5074250265 @default.
• W2989666329 creator A5075891845 @default.
• W2989666329 creator A5076667777 @default.
• W2989666329 creator A5076861872 @default.
• W2989666329 creator A5082180580 @default.
• W2989666329 creator A5085850492 @default.
• W2989666329 creator A5089930630 @default.
• W2989666329 date "2019-11-13" @default.
• W2989666329 modified "2023-10-18" @default.
• W2989666329 title "Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins" @default.
• W2989666329 doi "https://doi.org/10.1182/blood-2019-130549" @default.
• W2989666329 hasPublicationYear "2019" @default.
• W2989666329 type Work @default.
• W2989666329 sameAs 2989666329 @default.
• W2989666329 citedByCount "0" @default.
• W2989666329 crossrefType "journal-article" @default.
• W2989666329 hasAuthorship W2989666329A5005661878 @default.
• W2989666329 hasAuthorship W2989666329A5006261099 @default.
• W2989666329 hasAuthorship W2989666329A5012712111 @default.
• W2989666329 hasAuthorship W2989666329A5017218287 @default.
• W2989666329 hasAuthorship W2989666329A5022352605 @default.
• W2989666329 hasAuthorship W2989666329A5023112790 @default.
• W2989666329 hasAuthorship W2989666329A5023676277 @default.
• W2989666329 hasAuthorship W2989666329A5023902781 @default.
• W2989666329 hasAuthorship W2989666329A5027278060 @default.
• W2989666329 hasAuthorship W2989666329A5027328800 @default.
• W2989666329 hasAuthorship W2989666329A5027607604 @default.
• W2989666329 hasAuthorship W2989666329A5033004996 @default.
• W2989666329 hasAuthorship W2989666329A5037115007 @default.
• W2989666329 hasAuthorship W2989666329A5039325835 @default.
• W2989666329 hasAuthorship W2989666329A5039865368 @default.
• W2989666329 hasAuthorship W2989666329A5040526903 @default.
• W2989666329 hasAuthorship W2989666329A5043526996 @default.
• W2989666329 hasAuthorship W2989666329A5046430988 @default.
• W2989666329 hasAuthorship W2989666329A5047985390 @default.
• W2989666329 hasAuthorship W2989666329A5049272086 @default.
• W2989666329 hasAuthorship W2989666329A5049711954 @default.
• W2989666329 hasAuthorship W2989666329A5049971068 @default.
• W2989666329 hasAuthorship W2989666329A5055000089 @default.
• W2989666329 hasAuthorship W2989666329A5060671712 @default.
• W2989666329 hasAuthorship W2989666329A5060982277 @default.
• W2989666329 hasAuthorship W2989666329A5063875415 @default.
• W2989666329 hasAuthorship W2989666329A5064538334 @default.
• W2989666329 hasAuthorship W2989666329A5068511166 @default.
• W2989666329 hasAuthorship W2989666329A5069655687 @default.
• W2989666329 hasAuthorship W2989666329A5070668676 @default.
• W2989666329 hasAuthorship W2989666329A5074250265 @default.
• W2989666329 hasAuthorship W2989666329A5075891845 @default.
• W2989666329 hasAuthorship W2989666329A5076667777 @default.
• W2989666329 hasAuthorship W2989666329A5076861872 @default.
• W2989666329 hasAuthorship W2989666329A5082180580 @default.
• W2989666329 hasAuthorship W2989666329A5085850492 @default.
• W2989666329 hasAuthorship W2989666329A5089930630 @default.
• W2989666329 hasBestOaLocation W29896663291 @default.
• W2989666329 hasConcept C104317684 @default.
• W2989666329 hasConcept C134459356 @default.
• W2989666329 hasConcept C14036430 @default.
• W2989666329 hasConcept C175114707 @default.
• W2989666329 hasConcept C25602115 @default.
• W2989666329 hasConcept C27740335 @default.
• W2989666329 hasConcept C2775895488 @default.
• W2989666329 hasConcept C2778540781 @default.
• W2989666329 hasConcept C2908868211 @default.
• W2989666329 hasConcept C41091548 @default.
• W2989666329 hasConcept C502942594 @default.
• W2989666329 hasConcept C54355233 @default.

• next